Piramal Pharma reported a significant improvement in operating performance for the quarter ended June 30, 2026, with consolidated revenue from operations rising 17% to ₹2,270 crore. The group’s EBITDA surged 72% year-on-year to ₹285 crore, expanding margins to 12.5% from 8.5% in Q1FY26, driven by operational leverage across its Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and Piramal Consumer Healthcare (PCH) businesses. Despite the strong top-line and operating profit growth, the consolidated net loss narrowed to ₹69 crore from ₹102 crore before exceptional items in the prior year, as high depreciation and interest costs continued to weigh on the bottom line.

The Board of Directors approved the unaudited financial results on July 29, 2026, in compliance with Regulation 33 of the SEBI Listing Regulations. Statutory auditors Suresh Surana & Associates LLP conducted a limited review of the standalone and consolidated results. The company operates in a single segment, and no exceptional items were recorded during the current quarter, contrasting with Q1FY26 which included a one-time insolvency gain of ₹21 crore.

Financial Performance Overview

Standalone revenue from operations rose to ₹1,124.95 crore from ₹969.88 crore in Q1FY26. Standalone net profit remained flat at ₹113.48 crore compared to ₹113.14 crore in the prior year. On a consolidated basis, total income increased 18% to ₹2,359 crore, supported by other income of ₹89 crore. Total expenses stood at ₹2,386 crore, with material costs rising 23% to ₹852 crore and employee benefits increasing 9% to ₹676 crore. Depreciation expenses climbed 13% to ₹224 crore, while interest expenses remained stable at ₹88 crore.

The table below summarises the key consolidated financial metrics for the quarter:

Segment-Wise Growth Drivers

All three business verticals contributed to the top-line expansion. The CDMO segment led the charge with a 19% revenue increase to ₹1,187 crore, fueled by healthy order inflows, improved utilization across India and overseas sites, and an enhanced commercial team. CHG revenue grew 17% to ₹743 crore, maintaining market leadership in US inhalation anesthesia (Sevoflurane) with a 48% value share and intrathecal therapy. PCH revenue rose 15% to ₹347 crore, driven by 23% growth in Power Brands and 40% expansion in e-commerce sales.

What the Numbers Show

The substantial divergence between EBITDA growth (72%) and net loss reduction highlights the impact of fixed cost structures on bottom-line profitability. While operating leverage successfully expanded margins by 400 basis points, high depreciation (₹224 crore) and interest costs (₹88 crore) continue to pressure net earnings. The absence of exceptional items in Q1FY27 provides a clearer view of operational performance, indicating that the core business is generating stronger cash flows despite the reported net loss. The sustained contribution from associates (₹20 crore share of profit) further supports the group's overall financial stability.

Piramal Pharma Limited has released the audio recording of its conference call regarding the unaudited financial results for the quarter ended June 30, 2026 (Q1FY27). The call, held on July 30, 2026, covered both standalone and consolidated performance metrics for the period. Investors and stakeholders can access the recording directly through the company’s official website at https://www.piramalpharma.com/financial-reports .

The disclosure was made in continuation of a letter dated July 20, 2026, and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Maneesh Sharma, Company Secretary & Compliance Officer of Piramal Pharma Limited, signed the communication notifying the exchanges.

Disclosure Details

The company notified both BSE Limited and the National Stock Exchange of India Limited regarding the availability of the recording. The filing confirms that the audio file is now public record for stakeholder review.

Regulatory Compliance

The release of the conference call recording is a standard compliance requirement under Indian securities regulations. It ensures transparency and provides equal access to information for all shareholders following the announcement of quarterly financial results. No specific financial figures were detailed in this particular notification, as it serves solely to direct investors to the audio archive.